Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Highlights

Highlights September 1, 2015 Volume 314, Number 9 In This Issue of JAMA Pages 851-964 Research Opinion Viewpoint Eff ect of Finerenone in Patients With Diabetic Nephropathy 884 869 Evaluation of Flibanserin: Science In a randomized, placebo-controlled multicenter trial that enrolled 823 patients with and Advocacy at the FDA diabetic nephropathy who were receiving angiotensin-converting enzyme inhibitor or WF Gellad, KE Flynn, and GC Alexander angiotensin receptor blocker therapy, Bakris and colleagues found that the addition of 871 Specialty Society Clinical Practice fi nerenone—a novel nonsteroidal mineralocorticoid receptor antagonist—improved the Guidelines: Time for Evolution urinary albumin-creatinine ratio in a dose-dependent manner. or Revolution? D Classen and LA Mermel Related Article 940 873 Body-Fixed Sensors for Parkinson Disease Molecular Diagnostic Yield in Children With ASD 895 A Mirelman, N Giladi, and JM Hausdorff Autism spectrum disorder (ASD) represents a group of neurodevelopmental conditions 875 Learning From the Past to Measure that vary in clinical presentation and outcome. In a population-based sample of 258 un- the Future related children with ASD, Tammimies and colleagues assessed the molecular diagnostic CK Cassel and R Kronick yield of chromosomal microarray analysis and whole-exome sequencing. The authors re- A Piece of My Mind port greater diagnostic http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Highlights

JAMA , Volume 314 (9) – Sep 1, 2015
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/highlights-oZM4UnACQB

References (0)

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Medical Association
Copyright
Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2014.11949
Publisher site
See Article on Publisher Site

Abstract

September 1, 2015 Volume 314, Number 9 In This Issue of JAMA Pages 851-964 Research Opinion Viewpoint Eff ect of Finerenone in Patients With Diabetic Nephropathy 884 869 Evaluation of Flibanserin: Science In a randomized, placebo-controlled multicenter trial that enrolled 823 patients with and Advocacy at the FDA diabetic nephropathy who were receiving angiotensin-converting enzyme inhibitor or WF Gellad, KE Flynn, and GC Alexander angiotensin receptor blocker therapy, Bakris and colleagues found that the addition of 871 Specialty Society Clinical Practice fi nerenone—a novel nonsteroidal mineralocorticoid receptor antagonist—improved the Guidelines: Time for Evolution urinary albumin-creatinine ratio in a dose-dependent manner. or Revolution? D Classen and LA Mermel Related Article 940 873 Body-Fixed Sensors for Parkinson Disease Molecular Diagnostic Yield in Children With ASD 895 A Mirelman, N Giladi, and JM Hausdorff Autism spectrum disorder (ASD) represents a group of neurodevelopmental conditions 875 Learning From the Past to Measure that vary in clinical presentation and outcome. In a population-based sample of 258 un- the Future related children with ASD, Tammimies and colleagues assessed the molecular diagnostic CK Cassel and R Kronick yield of chromosomal microarray analysis and whole-exome sequencing. The authors re- A Piece of My Mind port greater diagnostic

Journal

JAMA – American Medical Association

Published: Sep 1, 2015

There are no references for this article.